Renaissance of targeting molecules for melanoma

Ekaterina Dadachova, Arturo Casadevall

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Malignant melanoma affects approximately 40,000 new patients each year in the United States and an estimated 100,000 people worldwide. There is no satisfactory treatment for patients with metastatic melanoma that have an estimated 5-year survival of 6%. The potential of radioimmunotherapy (RIT) for the treatment of metastatic melanoma was recognized very early by RIT pioneers when murine melanoma was successfully treated by DeNardo, and later when Larson reported a shrinkage of tumor in a patient with metastatic melanoma treated with 131I-labeled Fab′ fragments of a mAb against high-molecular-weight melanoma-associated antigen. Despite successes in the 1980s, RIT of melanoma did not develop into a clinical modality. The reasons for this are complex. In recent years, RIT has made an impression, as evidenced by the recent approval of Zevalin® and Bexxar® (anti-CD20 mAbs labeled with 90Y and 131I, respectively). Now there is a "window of opportunity" for RIT to become an effective therapy for metastatic melanoma. Surface antigen GD3 has been evaluated in patients as a potential target for melanoma RIT; pretargeting the administration of antibodies and intralesional administration of an antibody labeled with potent alpha-emitter 213-Bismuth have shown promise in clinical studies. Melanin, the pigment that gives melanoma its name, has emerged as a novel antigen for delivery of radioactivity to the tumors by antimelanin antibody. Simultaneously, radiolabeled metal-cyclized alpha-MSH peptide analogs and melanin-binding peptides are being developed as targeting molecules for melanoma. Overall, we are hopeful that targeted radionuclide therapy of metastatic melanoma will become a reality within the next few years.

Original languageEnglish (US)
Pages (from-to)545-552
Number of pages8
JournalCancer Biotherapy and Radiopharmaceuticals
Volume21
Issue number6
DOIs
StatePublished - 2006

Fingerprint

Melanoma
Radioimmunotherapy
Melanins
Renaissance
Neoplasm Antibodies
alpha-MSH
Peptides
Immunoglobulin Fab Fragments
Bismuth
Antibodies
Therapeutics
Surface Antigens
Radioisotopes
Radioactivity
Names
Metals
Antigens
Survival

Keywords

  • Antimelanin antibodies
  • Melanin
  • Melanoma
  • Radioimmunotherapy
  • Radiolabeled peptides
  • Surface antigens

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Renaissance of targeting molecules for melanoma. / Dadachova, Ekaterina; Casadevall, Arturo.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 21, No. 6, 2006, p. 545-552.

Research output: Contribution to journalArticle

Dadachova, Ekaterina ; Casadevall, Arturo. / Renaissance of targeting molecules for melanoma. In: Cancer Biotherapy and Radiopharmaceuticals. 2006 ; Vol. 21, No. 6. pp. 545-552.
@article{39f5870c89fa4813b5f86122ea6b8882,
title = "Renaissance of targeting molecules for melanoma",
abstract = "Malignant melanoma affects approximately 40,000 new patients each year in the United States and an estimated 100,000 people worldwide. There is no satisfactory treatment for patients with metastatic melanoma that have an estimated 5-year survival of 6{\%}. The potential of radioimmunotherapy (RIT) for the treatment of metastatic melanoma was recognized very early by RIT pioneers when murine melanoma was successfully treated by DeNardo, and later when Larson reported a shrinkage of tumor in a patient with metastatic melanoma treated with 131I-labeled Fab′ fragments of a mAb against high-molecular-weight melanoma-associated antigen. Despite successes in the 1980s, RIT of melanoma did not develop into a clinical modality. The reasons for this are complex. In recent years, RIT has made an impression, as evidenced by the recent approval of Zevalin{\circledR} and Bexxar{\circledR} (anti-CD20 mAbs labeled with 90Y and 131I, respectively). Now there is a {"}window of opportunity{"} for RIT to become an effective therapy for metastatic melanoma. Surface antigen GD3 has been evaluated in patients as a potential target for melanoma RIT; pretargeting the administration of antibodies and intralesional administration of an antibody labeled with potent alpha-emitter 213-Bismuth have shown promise in clinical studies. Melanin, the pigment that gives melanoma its name, has emerged as a novel antigen for delivery of radioactivity to the tumors by antimelanin antibody. Simultaneously, radiolabeled metal-cyclized alpha-MSH peptide analogs and melanin-binding peptides are being developed as targeting molecules for melanoma. Overall, we are hopeful that targeted radionuclide therapy of metastatic melanoma will become a reality within the next few years.",
keywords = "Antimelanin antibodies, Melanin, Melanoma, Radioimmunotherapy, Radiolabeled peptides, Surface antigens",
author = "Ekaterina Dadachova and Arturo Casadevall",
year = "2006",
doi = "10.1089/cbr.2006.21.545",
language = "English (US)",
volume = "21",
pages = "545--552",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Renaissance of targeting molecules for melanoma

AU - Dadachova, Ekaterina

AU - Casadevall, Arturo

PY - 2006

Y1 - 2006

N2 - Malignant melanoma affects approximately 40,000 new patients each year in the United States and an estimated 100,000 people worldwide. There is no satisfactory treatment for patients with metastatic melanoma that have an estimated 5-year survival of 6%. The potential of radioimmunotherapy (RIT) for the treatment of metastatic melanoma was recognized very early by RIT pioneers when murine melanoma was successfully treated by DeNardo, and later when Larson reported a shrinkage of tumor in a patient with metastatic melanoma treated with 131I-labeled Fab′ fragments of a mAb against high-molecular-weight melanoma-associated antigen. Despite successes in the 1980s, RIT of melanoma did not develop into a clinical modality. The reasons for this are complex. In recent years, RIT has made an impression, as evidenced by the recent approval of Zevalin® and Bexxar® (anti-CD20 mAbs labeled with 90Y and 131I, respectively). Now there is a "window of opportunity" for RIT to become an effective therapy for metastatic melanoma. Surface antigen GD3 has been evaluated in patients as a potential target for melanoma RIT; pretargeting the administration of antibodies and intralesional administration of an antibody labeled with potent alpha-emitter 213-Bismuth have shown promise in clinical studies. Melanin, the pigment that gives melanoma its name, has emerged as a novel antigen for delivery of radioactivity to the tumors by antimelanin antibody. Simultaneously, radiolabeled metal-cyclized alpha-MSH peptide analogs and melanin-binding peptides are being developed as targeting molecules for melanoma. Overall, we are hopeful that targeted radionuclide therapy of metastatic melanoma will become a reality within the next few years.

AB - Malignant melanoma affects approximately 40,000 new patients each year in the United States and an estimated 100,000 people worldwide. There is no satisfactory treatment for patients with metastatic melanoma that have an estimated 5-year survival of 6%. The potential of radioimmunotherapy (RIT) for the treatment of metastatic melanoma was recognized very early by RIT pioneers when murine melanoma was successfully treated by DeNardo, and later when Larson reported a shrinkage of tumor in a patient with metastatic melanoma treated with 131I-labeled Fab′ fragments of a mAb against high-molecular-weight melanoma-associated antigen. Despite successes in the 1980s, RIT of melanoma did not develop into a clinical modality. The reasons for this are complex. In recent years, RIT has made an impression, as evidenced by the recent approval of Zevalin® and Bexxar® (anti-CD20 mAbs labeled with 90Y and 131I, respectively). Now there is a "window of opportunity" for RIT to become an effective therapy for metastatic melanoma. Surface antigen GD3 has been evaluated in patients as a potential target for melanoma RIT; pretargeting the administration of antibodies and intralesional administration of an antibody labeled with potent alpha-emitter 213-Bismuth have shown promise in clinical studies. Melanin, the pigment that gives melanoma its name, has emerged as a novel antigen for delivery of radioactivity to the tumors by antimelanin antibody. Simultaneously, radiolabeled metal-cyclized alpha-MSH peptide analogs and melanin-binding peptides are being developed as targeting molecules for melanoma. Overall, we are hopeful that targeted radionuclide therapy of metastatic melanoma will become a reality within the next few years.

KW - Antimelanin antibodies

KW - Melanin

KW - Melanoma

KW - Radioimmunotherapy

KW - Radiolabeled peptides

KW - Surface antigens

UR - http://www.scopus.com/inward/record.url?scp=33846633608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846633608&partnerID=8YFLogxK

U2 - 10.1089/cbr.2006.21.545

DO - 10.1089/cbr.2006.21.545

M3 - Article

C2 - 17257069

AN - SCOPUS:33846633608

VL - 21

SP - 545

EP - 552

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 6

ER -